Phase 1RecruitingPriority 4 · Lower priorityNCT07220993
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Plain-language summary
This trial is testing CD7-directed CAR-T cell therapy for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 2 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Lymphoma came back or did not respond to prior treatment
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
CD7.CAR/28zeta T Cells (GENETIC): Fourdose levels will be evaluated: Dose level one: 1×10\^7 cells/m\^2 Dose level two: 3×10\^7 cells/m\^2 Dose level three: 5x10\^7 cells/m\^2 Dose level four: 1×10\^8 cells/m\^2
CD7.CAR/28zeta T Cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details